Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A2 | Q05940 | 10/20 | 0.43 |
| ▸ | RORC | P51449 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2762408 | 0.89 | SLC18A2 (0.44) | SLC18A2RORCSLC6A3HTR2A | |
| SCHEMBL2198983 | 0.88 | RORC (0.43) | SLC18A2RORCSLC6A3HTR2ATSHR | |
| SCHEMBL2199609 | 0.85 | SLC6A3 (0.47) | SLC18A2RORCSLC6A3HTR2ATSHR | |
| SCHEMBL2197844 | 0.84 | SLC6A3 (0.43) | SLC18A2RORCSLC6A3HTR2ATSHR | |
| SCHEMBL2762002 | 0.82 | PDE4B (0.45) | SLC18A2SLC6A3HTR2ATSHRHTT | |
| SCHEMBL2196703 | 0.81 | PDE4A (0.44) | SLC18A2SLC6A3HTR2ATSHRHTT | |
| SCHEMBL2197505 | 0.81 | RORC (0.68) | SLC18A2RORCSLC6A3HTR2A | |
| SCHEMBL2198121 | 0.80 | TSHR (0.44) | SLC6A3TSHRHTT | |
| SCHEMBL14276807 | 0.80 | TSHR (0.44) | SLC6A3TSHRHTT | |
| SCHEMBL2198761 | 0.80 | HTT (0.41) | SLC18A2SLC6A3TSHRHTTMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977372-B2 | Ortho aminoamides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977372-B2 | Ortho aminoamides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977372-B2 | Ortho aminoamides for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2011-07-12 | — | — | US | disclosed |
| WO-2010094678-A1 | NOVEL ORTHO-AMINOAMIDES FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2010-08-26 | — | — | WO | disclosed |
| US-20100216806-A1 | ORTHO AMINOAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216806-A1 | ORTHO AMINOAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE, INC. | 2010-08-26 | — | — | US | disclosed |
| US-20100216806-A1 | ORTHO AMINOAMIDES FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE, INC. | 2010-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100216806-A1 | ORTHO AMINOAMIDES FOR THE TREATMENT OF CANCER | HDAC5, HDAC1, HDAC4 | SLC18A2 2805/4885RORC 1997/4885SLC6A3 4126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.